A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-0125PMID 20534736PMCID PMC2940965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

  2010cited by this paper
• Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.

  2010cited by this paper
• Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma.

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

  2010cited by this paper
• Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

  2009influential reference
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

  2009cited by this paper
• Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

  2008cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  2007cited by this paper
• Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

  2007cited by this paper
• Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

  2007cited by this paper
• Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy.

  2006influential reference
• Lung cancer: computerized quantification of tumor response--initial results.

  2006cited by this paper
• Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  2004cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000influential reference
• Measuring response in solid tumors: unidimensional versus bidimensional measurement.

  1999influential reference
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• The effect of measuring error on the results of therapeutic trials in advanced cancer

  1976cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper

• From dimensions through dynamics to outcomes – lymph nodes and skin assessments predict CTCL outcomes

  2025cites this paper
• LinGuinE: Longitudinal Guidance Estimation for Volumetric Lung Tumour Segmentation

  2025cites this paper
• Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories

  2025cites this paper
• Analysis of correlation of pre-therapeutic assessment and the final diagnosis in endometrial cancer: role of tumor volume in the magnetic resonance imaging

  2023cites this paper
• Exploring the significance of tumor volume in endometrial cancer: Clinical pathological features, prognosis, and adjuvant therapies

  2023cites this paper
• Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review.

  2023cites this paper
• Role of tumor volume in endometrial cancer: An imaging analysis and prognosis significance

  2023cites this paper
• Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

  2022cites this paper
• Tumor Size Measurements for Predicting Hodgkin’s and Non-Hodgkin’s Lymphoma Response to Treatment

  2022cites this paper
• Treatment evaluation and prognosis prediction using radiomics in clinical practice

  2021cites this paper
• CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.

  2021cites this paper
• Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions

  2021cites this paper
• Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

  2021cites this paper
• Response Assessment to Cancer Therapy

  2021cites this paper
• Tumor volume is more reliable to predict nodal metastasis in non-small cell lung cancer of 3.0 cm or less in the greatest tumor diameter

  2020cites this paper
• Tumor volume is more reliable to predict nodal metastasis in non-small cell lung cancer of 3 cm or less in diameter

  2020cites this paper
• The Study of Tumor Volume as a Prognostic Factor in T Staging System for Non-Small Cell Lung Cancer: An Exploratory Study

  2020cites this paper
• Radiomics and Imaging Genomics for Evaluation of Tumor Response

  2020cites this paper
• Response Assessment and Follow-Up by Imaging in Lung Tumours

  2020cites this paper
• Imaging Analyses of Bone Tumors.

  2020cites this paper
• The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer

  2020cites this paper
• Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

  2020cites this paper
• Conventional Tumor Response Criteria and Limitations

  2020cites this paper
• Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics

  2020cites this paper
• ASO Author Reflections: Which Is a Better Way to Describe Tumor Size of Lung Cancer: Tumor Volume or Diameter?

  2019cites this paper
• Comparing the diagnostic value of 18F-FDG-PET/CT versus CT for differentiating benign and malignant solitary pulmonary nodules: a meta-analysis.

  2019cites this paper
• A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology

  2019cites this paper
• The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base.

  2019cites this paper
• Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer

  2019cites this paper
• Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements Using Radiomics.

  2019cites this paper
• Use of Crowd Innovation to Develop an Artificial Intelligence–Based Solution for Radiation Therapy Targeting

  2019cites this paper
• Distinguishing metastases from benign adrenal masses: what can CT texture analysis do?

  2018cites this paper
• Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases

  2018cites this paper
• Radiomic features analysis in computed tomography images of lung nodule classification

  2018cites this paper
• Best Response According to RECIST During First‐line EGFR‐TKI Treatment Predicts Survival in EGFR Mutation‐positive Non–Small‐cell Lung Cancer Patients

  2018cites this paper
• Lymph node segmentation by dynamic programming and active contours.

  2018cites this paper
• Defining the biological and clinical basis of radiomics

  2018cites this paper
• Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond.

  2018cites this paper
• Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

  2017cites this paper
• Volume versus diameter assessment of small pulmonary nodules in CT lung cancer screening.

  2017cites this paper
• The effects of iterative reconstruction in CT on low-contrast liver lesion volumetry: a phantom study

  2017cites this paper
• Systematic analysis of measurement variability in lung cancer with multidetector computed tomography

  2017cites this paper
• The prognostic impact of tumor volume on stage I non-small cell lung cancer.

  2017cites this paper
• Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status

  2017cites this paper
• Quantitative Imaging in Cancer Clinical Trials

  2016influential citation
• Detectable change of lung nodule volume with CT in a phantom study with high and low signal to background contrast

  2016cites this paper
• The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review.

  2016cites this paper
• Semantics Features : Phenotype Quantification by a Radiologist ’ s Expert Eye

  2016cites this paper
• Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

  2016cites this paper
• Ultrasonography as the Gold Standard for In Vivo Volumetric Determination of Chemically-induced Mammary Tumors.

  2016cites this paper
• A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology

  2016cites this paper
• Assessment of glioma response to radiotherapy using 3D pulsed-continuous arterial spin labeling and 3D segmented volume.

  2016cites this paper
• Scientific Advances Shaping the Future Roles of Oncology Nurses.

  2016cites this paper
• Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study.

  2016cites this paper
• Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

  2016cites this paper
• Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC

  2016cites this paper
• Quantitative Computed Tomography Imaging Biomarkers in the Diagnosis and Management of Lung Cancer

  2015cites this paper
• Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer

  2015cites this paper
• Chapter 10 – Translational Medicine and Biomarkers

  2015cites this paper
• Evaluation of an interactive science publishing tool: toward enabling three-dimensional analysis of medical images.

  2015cites this paper
• Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

  2015cites this paper
• Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

  2015cites this paper
• Modernizing Measurement of Tumor Response to Therapy: Application to Immunotherapeutics

  2015cites this paper
• Changes of lung tumour volume on CT - prediction of the reliability of assessments

  2015cites this paper
• Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?

  2014cites this paper
• Tumour Volume Assessment in Gastric Cancer

  2014cites this paper
• Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses

  2014cites this paper
• Effect of Kernels Used for the Reconstruction of MDCT Datasets on the Semi-Automated Segmentation and Volumetry of Liver Lesions

  2014cites this paper
• Volume estimation of multi-density nodules with thoracic CT

  2014cites this paper
• Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme

  2014cites this paper
• Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

  2014cites this paper
• Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm

  2014cites this paper
• Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm

  2014cites this paper
• Test–Retest Reproducibility Analysis of Lung CT Image Features

  2014cites this paper
• State of the art: Response assessment in lung cancer in the era of genomic medicine.

  2014influential citation
• Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.

  2014cites this paper
• Knowledge-fused Identification of Condition-specific Rewiring of Dependencies in Biological Networks

  2014cites this paper
• Monitoring Responses to Therapy in Oncology

  2014cites this paper
• Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials

  2014cites this paper
• Progression-Free Survival The Imaging Viewpoint: How Imaging Affects Determination of

  2013cites this paper
• Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field.

  2013cites this paper
• The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival

  2013cites this paper
• Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses.

  2013cites this paper
• Minimum detectable change in lung nodule volume in a phantom CT study.

  2013cites this paper
• Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals.

  2013cites this paper
• Special session on validating new procedures

  2013cites this paper
• Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy

  2013cites this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cites this paper
• Response phenotype as a predictive biomarker to guide treatment with targeted therapies.

  2013cites this paper
• Therapeutics , Targets , and Chemical Biology Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR

  2013cites this paper
• Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR Citation

  2013cites this paper
• Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

  2013cites this paper
• mTOR , ATM and ATR Characterization of Torin 2 , an ATP-competitive inhibitor of

  2013cites this paper
• ATM , and ATR Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR

  2013cites this paper
• Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

  2013cites this paper
• Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

  2013cites this paper
• Clinical Trials Toolbox RECIST : No Longer the Sharpest Tool in the Oncology

  2012cites this paper
• Promise and pitfalls of quantitative imaging in oncology clinical trials.

  2012cites this paper
• Drug development and clinical trials—the path to an approved cancer drug

  2012cites this paper
• Optimal use of imaging to guide treatment decisions for kidney cancer.

  2012cites this paper